Continuation versus Interruption of Oral Anticoagulation during TAVI.
Dirk Jan van GinkelWillem L BorHugo M AartsChristophe DuboisOle De BackerMaxim J P RooijakkersLiesbeth RosseelLeo VeenstraFrank van der KleyKees H van BergeijkNicolas M D A van MieghemPierfrancesco AgostoniMichiel VoskuilCarl E SchotborghAlexander J J IJsselmuidenJan A S Van Der HeydenRenicus S HermanidesEmanuele BarbatoDarren MylotteEnrico FabrisPeter FrambachKarl DujardinBert FerdinandeJoyce PeperBenno J W M RensingLeo TimmersMartin J SwaansJorn BrouwerVincent J NijenhuisDaniel C OverduinTom AdriaenssensYusuke KobariPieter A VriesendorpJose M Montero-CabezasHicham El JattariJonathan HalimBen J L Van den BrandenRemigio LeonoraMarc VanderheydenMichael LauterbachJoanna J WykrzykowskaArnoud W J van 't HofNiels van RoyenJan G P TijssenRonak DelewiJurriën M Ten Bergnull nullPublished in: The New England journal of medicine (2024)
In patients undergoing TAVI with a concomitant indication for oral anticoagulation, periprocedural continuation was not noninferior to interruption of oral anticoagulation during TAVI with respect to the incidence of a composite of death from cardiovascular causes, stroke, myocardial infarction, major vascular complications, or major bleeding at 30 days. (Funded by the Netherlands Organization for Health Research and Development and the St. Antonius Research Fund; POPular PAUSE TAVI ClinicalTrials.gov number, NCT04437303.).
Keyphrases
- atrial fibrillation
- transcatheter aortic valve implantation
- aortic valve
- transcatheter aortic valve replacement
- aortic stenosis
- venous thromboembolism
- patients undergoing
- direct oral anticoagulants
- heart failure
- catheter ablation
- risk factors
- left ventricular
- percutaneous coronary intervention
- ejection fraction
- health insurance